Radiat Oncol J.  2023 Dec;41(4):248-257. 10.3857/roj.2023.00248.

A comparison of conventional and accelerated hypofractionated radiotherapy in definitive chemoradiation for locally advanced head and neck carcinoma: a retrospective cohort study

• Tripathy A
• Muzumder S
• Srikantia N
• Babu A
• Sebastian MJ
• Udayashankar AH
• Vashishta GD
• Raj JM

• KMID: 2549373
• DOI: http://doi.org/10.3857/roj.2023.00248

Abstract

Purpose
The study evaluates accelerated hypofractionated radiotherapy (AHRT) compared to conventional fractionation radiotherapy (CFRT) in patients with locally advanced head and neck cancer (LAHNC) receiving definitive chemoradiation therapy.
Materials and Methods
The study includes a retrospective cohort analysis of 120 patients. CFRT arm (n = 65) received 2 Gy per fraction to a dose of 70 Gy over 7 weeks in a three-volume approach, whereas the AHRT arm (n = 55) received 2.2 Gy per fraction to a dose of 66 Gy in 6 weeks with a two-volume approach. The primary outcome was overall survival (OS).
Results
With a median follow-up of 18.9 months, 23 patients died in the AHRT arm, and 45 deaths in the CFRT arm. The median OS was 23.4 and 37.63 months in the CFRT and AHRT arms, respectively (hazard ratio [HR] = 0.709; 95% confidence interval [CI], 0.425–1.18; p = 0.189). The median time to loco-regional control was 33.3 months in the CFRT arm and was not reached in the patient group receiving AHRT (HR = 0.558; 95% CI, 0.30–1.03; p = 0.065). The median progression-free survival was 15.9 months in the CFRT arm and 26.9 months in the AFRT arm (HR = 0.801; 95% CI, 0.49–1.28; p = 0.357). Out of 11 acute toxic deaths, eight were in the CFRT arm.
Conclusion
The study showed a trend towards benefit in terms of locoregional control in the AHRT arm and similar OS. A longer follow-up of patients receiving AHRT is required to assess the benefit.

Keyword

Head and neck neoplasms; Accelerated hypo-fractionated radiotherapy; Overall survival; Toxicity; Local control; Chemoradiation